Transparency data

UK National Screening Committee

Updated 10 January 2024

This register records declarations made by members in respect of interests they have that are relevant to the remit of the UK National Screening Committee (UK NSC).

Professor Sir Mike Richards (chair)

• NHS England – consultancy on diagnostics programme
• Office for Life Sciences – advice on early diagnosis and treatment of cancer
• Medefer – member clinical advisory group
• Incisive Health – senior counsel
• Cancer Research UK – trustee
• carrying out a review of screening quality assurance services within NHS England

Dr Graham Shortland (vice-chair)

• healthcare equity interests
• Smith and Nephew shares

Professor Natalie Armstrong

• active academic researcher with externally-funded research portfolio, including co-investigator on the NIHR-funded SAFER study, looking at screening for atrial fibrillation and NIHR-funded PHAST study, looking at adding cardiovascular screening into AAA screening

• associate editor at the journal BMJ Quality & Safety, receiving an annual honorarium

Eleanor Cozens (PPV)

• none

Greg Fell

• vice-president of the Association of Directors of Public Health

Dr Rosalind Given-Wilson

• consultant radiologist at St Georges Hospital Foundation Trust and Parkside Hospital

• non executive director and vice-chair at Moorfields Eye Hospital Foundation Trust

Dr Sharon Hillier

• none

Professor Chris Hyde

• paid to provide advice to SkinAnalytics, an artificial intelligence (AI) developer for the diagnosis of suspected skin cancer lesions as part of its clinical advisory committee – they have no plans to use this technology in screening
• consultant to small diagnostics company (Clinical Design) manufacturing a digital urinalysis system, designs studies to help evaluate the device and receives monthly retainer for this service
• academically active and receives research grants to undertake evaluations of tests, including health technology assessments for UK NSC and NIHR; recently included work on AI for diabetic retinopathy screening and targeted screening for lung cancer
• University of Exeter (employer) is an approved supplier which, through open competition, may be awarded tender to develop evidence review products for the UK NSC

Professor Anneke Lucassen

• Genomics England Ethics advisory committee member

• UK Biobank ethics advisory committee member

Prof Bethany Shinkins

• co-investigator, through visiting professor title at the University of Leeds, on the Yorkshire Lung Screening Trial (YLST)

• co-investigator on a sub-study of YLST and an Innovate UK funded study (iDx-LUNG) – the projects’ commercial partners include Elypta, Roche Diagnostics, Oncimmune, Inivata and J&J

• collaborator on Yorkshire Kidney Screening Trial

• previously a collaborator on a SBRI-funded grant awarded to PinPoint Data Sciences to evaluate its risk prediction tool for cancer – and had worked with them on another SBRI grant that is also now complete. Prof Shinkins’ previous employer, the University of Leeds, has a royalty agreement with PinPoint Data Sciences which means the university is likely to benefit financially in the event of PinPoint being commercially successful

• member of Innovation Expert Advisory Group for the NHS Cancer Programme

• through current employer, the University of Warwick, works on NICE Diagnostic Assessment Reports, and also works with a research group, called Warwick Screening, which is a team involved in a range of publicly funded screening research and methodology development

Dr Anne-Marie Slowther

• co-investigator (co-author on submitted report) on NIHR funder research project: Valuing the benefits and harms of newborn and antenatal screening in health economic assessments (NIHR 127489)
• employed by University of Warwick (researchers from the university may apply for grant funding for research projects related to screening programmes)

Professor Sian Taylor-Phillips

• University of Warwick (employer) is an approved supplier which, through open competition, may be awarded tender to develop evidence review products for the UK NSC

• holds the following grants, for which employer (University of Warwick) receives funds:

  • evidence synthesis for the UK NSC and NICE; methods of evaluating screening tests (NIHR)
  • development of microbubble test for lymph node involvement for breast cancer (LiSENUS, NIHR, no intellectual property rights)
  • FAST MRI diagnostic yield for breast cancer (NIHR, no intellectual property rights)
  • evaluation of colorectal cancer tests (RECEDE, NIHR).
• serves on various trial management and steering groups with no financial reimbursement, including the AgeX breast screening extension trial since October 2022, and the PHAST abdominal aortic aneurism screening extension trial since March 2020